Emerging Treatment Options for Long-Term Obesity Management
During this webinar, Dr. Ryan and Dr. Frias discuss the newer and emerging treatment options for the management of obesity in T2DM patients. A special focus is placed on tirzepatide, a new agent for the management of T2D, and data about its rationale, efficacy, and safety are reviewed.
- Dual GLP-1/GIP co-agonists
- Efficacy and safety from major completed trials
- Ongoing trials
- Other emerging agents for obesity management
Primary care physicians, cardiologists, endocrinologists, nurses, nurse practitioners, physician assistants, and pharmacists.
After completing this activity, the participant should be better able to:
- Summarize the mechanisms of action, efficacy and safety of new and emerging therapies for long-term weight management in patients with type 2 diabetes and obesity, including novel dual GIP/GLP-1 receptor agonists
- Select appropriate T2DM patients who might benefit from treatment with newer dual GIP/GLP-1 receptor agonist
Donna Ryan, MD (Chair/Moderator)
Pennington Biomedical Research Center
Dr. Ryan discloses the following:
Speakers Bureau/Honoraria for non-CME: Novo Nordisk
Consultant/Advisory Board: Altimmune, Amgen, Boeringer Ingelheim, Calibrate, Epitomee, Gila Therapeutics, ifa Celtic, Jansen, Lilly, Novo Nordisk, real appeal (United Health),Roman, Scientific Intake, Wondr Health, Xeno Bioscience, Ysopia
Non-Mutual funds Stock Ownership/Stock options: Stock OPTIONS: Calibrate, Gila Therapeutics, Xeno Bioscience (returned in 2022), Epitomee, Roman and Scientific Intake
Juan Pablo Frías, MD (Faculty)
Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, CA
Dr. Frías discloses the following:
Grant/Research Support: Akero, AstraZeneca, Boehringer Ingelheim, BMS, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi
Speakers Bureau/Honoraria for non-CME: Eli Lilly, Merck, Sanofi
Consultant/Advisory Board: Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational grant provided by Lilly USA, LLC.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-379-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period November 15, 2022 through November 14, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.